CER Daily Newsfeed

The Comparative Effectiveness Research Daily Newsfeed®, known for short as the CER Daily Newsfeed®, offers the latest news, research and related information on comparative effectiveness research, real-world data and evidence, value assessment and other important health care topics. 

News from Wednesday, September 22, 2021


NPC Submits Comments on Medicare Physician Fee Schedule Proposed Rule

(9/21, National Pharmaceutical Council: E.V.I.dently Today) comments “The National Pharmaceutical Council submitted comments to the Centers for Medicare and Medicaid Services regarding the Medicare Program’s CY 2022 payment policies under the Physician Fee Schedule and other policy changes (‘CY 2022 PFS Proposed Rule’). The CY 2022 PFS Proposed Rule policies for physician quality programs affect measurement and improvement of care delivery and health outcomes for Medicare beneficiaries and can impact patients’ access to innovative therapies. NPC’s comments support CMS’ continued efforts to improve quality measurement, promote patient-centered care, and focus on health equity. We further recommend opportunities to enhance understanding of patient-reported outcomes and address barriers to medication access.” Full


Letting the Government Negotiate Drug Prices Won't Hurt Innovation

(9/22, Aaron S. Kesselheim and Jerry Avorn, The Washington Post) comments “...Negotiating drug prices based on a medication’s clinical benefits — the approach taken in the congressional plan — would ensure high reimbursement for drugs that offer meaningful value to patients while decreasing the incentives to create treatments that offer little that’s new. This is the approach taken in most of the industrialized world. Such reform would start to make drug pricing resemble the economics of almost every other product in the economy.” Full


Video: Goals of AD Therapy With Early Detection

(9/22, Neil B. Minkoff, MD, et al., The American Journal of Managed Care) “...[Richard Isaacson, MD:] We now have published studies that show comparative effectiveness research, which is a newer style of research where we try to analyze the real-world results or the real-world findings of lifestyle interventions and risk-factor reduction: interventions that modify risk factors and modify a person’s risk of cognitive decline. We have shown that these outcomes can be positive, cognitive outcomes can be improved, and risk can go down, so I hope that these models change things.” View Video


Vaccines Europe Makes the Case for Vaccine-Specific HTA

(9/21, Kari Oakes, Regulatory Focus) reports “...The vaccine-specific initiative would be part of a broader effort by the European Commission to institute common HTA methodologies and tools throughout the EU. Vaccines Europe, together with the European Federation of Pharmaceutical Industries and Associations’, is seeking to ensure that ‘the unique specificities of vaccines’ are taken into account when any proposed regulation is implemented; the groups also seek to avoid duplication of effort and ‘unnecessary administrative and regulatory barriers,’ according to the position paper.” Full

Press Releases

Aetion and Quinten Health Partner to Use AI and RWE to Reduce Research Timelines

(9/22, Aetion Press Release) “Quinten Health, a Paris-based AI solutions company, and Aetion, a global real-world evidence technology provider, announce a strategic partnership to offer a comprehensive and integrated range of RWE generation products and services. The aim of this partnership is to generate insights in near real time to reduce complexity, increase efficiency, and support rapid turn-around of insights for researchers around the world, across therapeutic areas, all in an effort to improve patient outcomes.” Full


NPC Comments on CMS' Proposed Medicare Shared Savings and Physician Fee Policies

September 13, 2021

National Pharmaceutical Council